Bioneer Corporation (064550) - Total Liabilities
Based on the latest financial reports, Bioneer Corporation (064550) has total liabilities worth ₩147.32 Billion KRW (≈ $99.83 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioneer Corporation - Total Liabilities Trend (2011–2024)
This chart illustrates how Bioneer Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore Bioneer Corporation long-term investment allocation to see how much of total assets are deployed in long-term investments.
Bioneer Corporation Competitors by Total Liabilities
The table below lists competitors of Bioneer Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sastasundar Ventures Limited
NSE:SASTASUNDR
|
India | Rs1.32 Billion |
|
Harrisons Holdings (Malaysia)
KLSE:5008
|
Malaysia | RM494.98 Million |
|
Mobile Infrastructure Corporation
NYSE MKT:BEEP
|
USA | $228.10 Million |
|
WiSoL CO.LTD
KQ:122990
|
Korea | ₩51.56 Billion |
|
Wealth First Portfolio Managers Limited
NSE:WEALTH
|
India | Rs92.53 Million |
|
Schloss Wachenheim AG
F:SWA
|
Germany | €260.86 Million |
|
Yirendai Ltd
NYSE:YRD
|
USA | $5.11 Billion |
|
Pha Lai Thermal Power JSC
VN:PPC
|
Vietnam | ₫865.81 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Bioneer Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 064550 total assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioneer Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioneer Corporation (2011–2024)
The table below shows the annual total liabilities of Bioneer Corporation from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩105.29 Billion ≈ $71.36 Million |
+30.62% |
| 2023-12-31 | ₩80.61 Billion ≈ $54.63 Million |
+28.49% |
| 2022-12-31 | ₩62.74 Billion ≈ $42.51 Million |
+5.67% |
| 2021-12-31 | ₩59.37 Billion ≈ $40.23 Million |
+30.31% |
| 2020-12-31 | ₩45.56 Billion ≈ $30.88 Million |
-11.52% |
| 2019-12-31 | ₩51.49 Billion ≈ $34.89 Million |
+61.83% |
| 2018-12-31 | ₩31.82 Billion ≈ $21.56 Million |
+0.85% |
| 2017-12-31 | ₩31.55 Billion ≈ $21.38 Million |
-16.08% |
| 2016-12-31 | ₩37.59 Billion ≈ $25.48 Million |
+0.38% |
| 2015-12-31 | ₩37.45 Billion ≈ $25.38 Million |
+0.80% |
| 2014-12-31 | ₩37.16 Billion ≈ $25.18 Million |
-8.02% |
| 2013-12-31 | ₩40.40 Billion ≈ $27.38 Million |
+10.05% |
| 2012-12-31 | ₩36.71 Billion ≈ $24.88 Million |
+11.94% |
| 2011-12-31 | ₩32.79 Billion ≈ $22.22 Million |
-- |
About Bioneer Corporation
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analys… Read more